Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.64 |
| ▸ | GNPAT | O15228 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 4/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | PAM | P19021 | 1/20 | 0.52 |
| ▸ | REN | P00797 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9571896 | 0.92 | CTSS (0.63) | LTA4HGNPATACECTSSCTSK | |
| SCHEMBL11113189 | 0.92 | CTSS (0.63) | LTA4HGNPATACECTSSCTSK | |
| SCHEMBL9571894 | 0.92 | CTSS (0.63) | LTA4HGNPATACECTSSCTSK | |
| SCHEMBL17732682 | 0.91 | GNPAT (0.60) | LTA4HGNPATACECTSSCTSK | |
| SCHEMBL7437335 | 0.89 | GNPAT (0.63) | GNPATACECTSSCTSKMME | |
| SCHEMBL30533197 | 0.89 | GNPAT (0.67) | LTA4HGNPATACECTSSCTSK | |
| SCHEMBL17732678 | 0.89 | GNPAT (0.67) | LTA4HGNPATACECTSSCTSK | |
| SCHEMBL30799905 | 0.89 | GNPAT (0.67) | LTA4HGNPATACECTSSCTSK | |
| SCHEMBL17732667 | 0.88 | GNPAT (0.56) | GNPATACECTSSCTSKMME | |
| SCHEMBL31651396 | 0.87 | GNPAT (0.61) | GNPATACECTSSCTSKMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | LTA4H 4132/4885GNPAT 3689/4885ACE 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.